Brief: Revance Therapeutics Q2 EPS USD -0.8
08/08/2023 21:05
Aug 08 (Reuters) - Revance Therapeutics Q2 product revenue USD 54.393 million. * Q2 operating expenses USD 123.633 million * Q2 operating income USD -65.499 million * Q2 net income USD -67.318 million
Recent news on Revance Therapeutics
See all newsBrief: Crown Laboratories and Revance Therapeutics Announce Expiration of Tender Offer
Brief: Crown Laboratories And Revance Amend A&R Merger Agreement
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-Kratos, Forward Air, Bank stocks
U.S. STOCKS ON THE MOVE-Henry Schein, natgas firms, Citigroup